The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease

Clinical Cardiology

Volumn 34, Issue 8, 2011, Pages 513-518

  Zeng, Wei Jie ^a   Lu, Xian Ling ^a   Xiong, Chang Ming ^a   Shan, Guang Liang ^b   Liu, Zhi Hong ^a   Ni, Xin Hai ^a   Gu, Qing ^a   Zhao, Zhi Hui ^a   Li, Jian Jun ^a   He, Jian Guo ^a  

^a Department of Cardiology   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIAC GLYCOSIDE; DIURETIC AGENT; SILDENAFIL; WARFARIN;

ADULT; ARTERIAL OXYGEN SATURATION; ARTICLE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; EXERCISE; FEMALE; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HUMAN; LUNG BLOOD FLOW; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; NOSE CONGESTION; OPEN STUDY; PATENT DUCTUS ARTERIOSUS; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; TINNITUS; WALKING;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE AGENTS; CHI-SQUARE DISTRIBUTION; CHINA; DUCTUS ARTERIOSUS, PATENT; EXERCISE TOLERANCE; FEMALE; HEART DEFECTS, CONGENITAL; HEART SEPTAL DEFECTS, ATRIAL; HEART SEPTAL DEFECTS, VENTRICULAR; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; MALE; OXYGEN; PIPERAZINES; PROSPECTIVE STUDIES; PURINES; SULFONES; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 80051549897     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20917     Document Type: Article

References (22)

1. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30: 2493-2537.
2. Beghetti M, Tissot C., Pulmonary arterial hypertension in congenital heart diseases. Semin Respir Crit Care Med. 2009; 30: 421-428.
3. van Albada ME, Berger RM., Pulmonary arterial hypertension in congenital cardiac diseaseâ-the need for refinement of the Evian-Venice classification. Cardiol Young. 2008; 18: 10-17. (Pubitemid 351228064)
4. Berger RM, Beghetti M, Galie N, et al. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. Int J Cardiol. 2010; 144: 373-378.
5. Wort SJ., Sildenafil in Eisenmenger syndrome: safety first. Int J Cardiol. 2007; 120: 314-316. (Pubitemid 47069571)
6. Lim ZS, Salmon AP, Vettukattil JJ, et al. Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. Int J Cardiol. 2007; 118: 178-182. (Pubitemid 46604774)
7. Chau EM, Fan KY, Chow WH., Effects of chronic sildenafil in patients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol. 2007; 120: 301-305. (Pubitemid 47069563)
8. Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart J. 2006; 151: e851-e855.
9. Garg N, Sharma MK, Sinha N., Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. Int J Cardiol. 2007; 120: 306-313. (Pubitemid 47069567)
10. Lu XL, Xiong CM, Shan GL, et al. Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. Cardiovasc Ther. 2010; 28: 350-355.
11. Brooks D, Solway S, Gibbons WJ., ATS statement on six-minute walk test. Am J Respir Crit Care Med. 2003; 167: 1287.
12. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005; 353: 2148-2157. (Pubitemid 41653106)
13. Diller GP, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation. 2005; 112: 828-835. (Pubitemid 41170068)
14. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346: 896-903. (Pubitemid 34984638)
15. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009; 119: 2894-2903.
16. Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. 2010; 121: 20-25.
17. Gupta A, Kerkar P., Sildenafil for pulmonary hypertension secondary to congenital heart diseases. Indian Heart J. 2007; 59: 342-345.
18. Ghofrani HA, Voswinckel R, Reichenberger F, et al. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J Am Coll Cardiol. 2004; 44: 1488-1496. (Pubitemid 39303954)
19. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002; 105: 2398-2403. (Pubitemid 34556392)
20. Corbin JD, Francis SH., Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem. 1999; 274: 13729-13732.
21. Tantini B, Manes A, Fiumana E, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol. 2005; 100: 131-138. (Pubitemid 40361605)
22. Barbera JA, Riverola A, Roca J, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994; 149: 423-429. (Pubitemid 24068990)